Developer docs
API playgroundTry for free, no card

Search company profiles

Alvotech

Full company profile

uuid00000ty

Namestring
Alvotech
Legal namestring
Alvotech hf
Websiteurl
alvotech.com
Company typeenum
Public
Founded yearint
2013
Descriptiontext

Alvotech is a global biotechnology company that develops, manufactures, and commercializes biosimilar versions of high-cost biologic medicines. Founded in 2013 and headquartered in Reykjavík, Iceland, the company operates a vertically integrated platform spanning cell line development, analytical characterization, clinical development, regulatory submissions, single-use bioreactor manufacturing (in Reykjavik and Jülich, Germany), and fill/finish (via the acquired Ivers-Lee facility in Burgdorf, Switzerland). The portfolio is focused exclusively on monoclonal antibody biosimilars across immunology, ophthalmology, oncology, and bone health, with five approved products globally (AVT02 adalimumab, AVT04 ustekinumab, AVT03 denosumab, AVT05 golimumab, AVT06 aflibercept) and nine candidates in the pipeline. Alvotech is publicly listed on NASDAQ (ALVO) and trades Swedish Depositary Receipts on Nasdaq Stockholm.

The company monetizes its biosimilars through a hybrid model: direct sales to wholesalers, distributors, and pharmacies in the United States where Alvotech is the Marketing Authorization Holder (e.g., Simlandi for adalimumab, Selarsdi for ustekinumab), combined with regional commercialization partnerships covering most other geographies. Teva handles the United States and select markets for multiple programs; Sandoz distributes in Canada, Australia, and New Zealand; Advanz Pharma leads European commercialization (including the December 2025 launch of Gobivaz, the first-in-market Simponi biosimilar); and Dr. Reddy's handles selected programs. Revenue is also generated through licensing royalties, milestone payments, and supply agreements with these partners. End customers are healthcare providers, government health systems, payers, wholesalers, and pharmacies across the US, Europe, Japan, China, Latin America, Africa, and the Middle East.

Alvotech reported FY2025 revenue of approximately $593 million and is guiding $650–700 million for FY2026. The company has financed growth through a mix of equity, convertible bonds, and senior debt, with a $965M GoldenTree-led refinancing in June 2024 and multiple subsequent capital raises in 2025–2026. The business faces near-term execution risk: an FDA Complete Response Letter in November 2025 regarding the Reykjavik manufacturing facility has delayed AVT05, triggered securities litigation, and pressured the share price, while the late-stage pipeline (AVT05, AVT06, AVT16/AVT80) is central to the 2026–2027 growth thesis. A leadership transition in early 2026 — Lisa Graver replacing founder Róbert Wessman as CEO — accompanies the operational recalibration.

Short descriptiontext

Alvotech is a global biotechnology company that develops and manufactures biosimilar monoclonal antibodies for immunology, ophthalmology, oncology, and bone health, commercializing them through global partners (Teva, Sandoz, Advanz, Dr. Reddy's) and direct US sales, with five approved biosimilars and nine pipeline candidates.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersReykjavík, Iceland
HQ citystring
Reykjavík
HQ countrystring
Iceland
HQ regionstring
Europe
Markets served

Serves global market

Offices10 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biosimilar medicines, monoclonal antibody development, biologics manufacturing, biopharmaceutical development, cell line engineering
Industry2 codes
PRIMARYHLAAAHAL
Biosimilar Commercialization & Market Access (pricing, tendering, interchangeability, distribution)
SECONDARYHLAGAMAD
Specialty Pharma & Biologics Distribution (GDP-compliant)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Supply Chain, Logistics & Cold Chain for Life Sciences
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biosimilar Pharmaceuticals
Social media profiles3 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Biosimilar product sales
TypeHardware Sales
Description

Revenue from the sale of approved biosimilars directly (where Alvotech is MAH) and through commercialization partners in multiple geographies. Includes AVT02 (adalimumab biosimilar) and other approved products.

2Licensing royalties and milestone payments
TypeLicensing Royalties
Description

Revenue from licensing, royalty, and milestone arrangements with commercial partners including Teva, Sandoz, Advanz Pharma, Dr. Reddy's, and Regeneron (settlement/licensing agreement). Includes upfront, milestone, and royalty components tied to development, regulatory, and commercial events.

3Supply and commercialization agreements
TypeManaged Services
Description

Revenue generated through supply and commercialization agreements with regional partners covering defined territories (e.g., Sandoz for Canada/Australia/New Zealand; Advanz Pharma for Europe).

Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Technology or R&D, Personnel, Marketing or Sales, Supply Chain
Pricing details1 tier
1Biosimilar medicines pricing not publicly disclosed
ModelOtherBilling cadencePay-as-you-go
Notes

Pricing is quote-based and negotiated with payers, distributors, and partners; not publicly listed.

GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Simlandi (adalimumab-ryvk)
Description

U.S. marketed biosimilar product for which Alvotech is the Marketing Authorization Holder in the U.S. (adalimumab biosimilar).

alvotech.com
+2 more records
Core offering1 text field

Alvotech develops, manufactures, and commercializes biosimilar medicines—biologic medicines that are highly similar to already-approved reference biologics—focused on monoclonal antibody therapies. The company operates a vertically integrated platform covering cell line development, process and analytical development, clinical studies, regulatory submissions, manufacturing, and fill/finish. It markets its products either directly in the US (where it is the Marketing Authorization Holder) or through regional commercialization partners (Teva, Sandoz, Advanz Pharma, Dr. Reddy's) across Europe, Canada, Australia, New Zealand, Japan, China, Latin America, Africa, and the Middle East.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • $593M in revenue (2025 reference figure in source)
+2 more records
Product and service7 records
1Simlandi (AVT02, adalimumab-ryvk)
CategoryBiosimilar pharmaceutical — immunology
Description

Biosimilar of Humira (adalimumab) for the treatment of immunology conditions including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis. Marketed by Alvotech in the US.

2Selarsdi (AVT04, ustekinumab-aekn)
CategoryBiosimilar pharmaceutical — immunology
Description

Biosimilar of Stelara (ustekinumab) for the treatment of immunology conditions including plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Marketed by Alvotech in the US.

3AVT03 (denosumab biosimilar)
4Gobivaz (AVT05, golimumab biosimilar)
CategoryBiosimilar pharmaceutical — immunology
Description

Biosimilar of Simponi (golimumab) for the treatment of inflammatory conditions including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. Marketed as Gobivaz in Europe by Advanz Pharma; marketed in the US by Teva (as AVT05) following FDA approval.

5AVT06 (aflibercept biosimilar)
CategoryBiosimilar pharmaceutical — ophthalmology
Description

Biosimilar of Eylea (aflibercept) for the treatment of ophthalmology conditions including neovascular (wet) age-related macular degeneration, diabetic macular edema, and other retinal disorders. Developed under partnership with Teva for US commercialization.

6AVT16 (vedolizumab biosimilar, proposed interchangeable)
CategoryBiosimilar pharmaceutical — gastroenterology
Description

Proposed interchangeable biosimilar of Entyvio (vedolizumab) for the treatment of ulcerative colitis and Crohn's disease. Developed under partnership with Teva Pharmaceutical Industries, with Alvotech handling development and manufacturing.

7AVT80 (vedolizumab biosimilar, subcutaneous)
CategoryBiosimilar pharmaceutical — gastroenterology
Description

Proposed subcutaneous biosimilar of Entyvio (vedolizumab) for the treatment of ulcerative colitis and Crohn's disease, complementing the intravenous AVT16 program. The successful PK study supports regulatory submissions for both products.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Teva is Alvotech's strategic commercialization partner for multiple biosimilars (including AVT05, AVT06, AVT16 and others). The partnership covers US commercialization and select global markets and represents one of Alvotech's most important commercial relationships.

2Sandoz
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Supply and commercialization agreement covering Canada, Australia, and New Zealand for Alvotech biosimilars. Sandoz distributes Alvotech's products in these regional markets under defined territory terms.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

European commercialization partner for Gobivaz (golimumab biosimilar / Simponi biosimilar) and additional Alvotech biosimilars. Advanz Pharma leads the European launch and distribution of these products.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic commercialization and co-development partner for AVT03 (denosumab biosimilar) and related biosimilar programs. The partnership supports Alvotech's reach into selected markets and shared development effort.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Settlement and licensing agreement related to AVT06 (Eylea / aflibercept biosimilar). Resolves patent dispute and enables Alvotech to develop and commercialize its aflibercept biosimilar under the terms of the agreement.

6Ivers-Lee (Burgdorf, Switzerland)
Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Assembly and packaging partner supporting Alvotech's fill/finish operations at the Burgdorf, Switzerland site.

7GlycoThera GmbH
Strategic tierMinorTypeStrategic or Co-development Partner
Description

R&D subsidiary contributing to Alvotech's biosimilar research and development capabilities.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Samsung Bioepis is a biosimilars-focused biotech with an approved portfolio spanning immunology (adalimumab, etanercept), ophthalmology (ranibizumab), and oncology (trastuzumab, bevacizumab). It is a direct competitor in monoclonal antibody biosimilars with overlapping therapeutic-area focus and global commercialization partnerships.

TypeDirect peer
Description

Celltrion is a South Korean biosimilars leader with approved products including infliximab (Remsima), rituximab (Truxima), trastuzumab (Herzuma), and adalimumab (Yuflyma). It is a direct competitor across immunology and oncology biosimilars with vertically integrated manufacturing and global commercial reach.

TypeDirect peer
Description

Biocon Biologics is a biosimilars-focused subsidiary of Biocon Limited with approved products including pegfilgrastim, trastuzumab, bevacizumab, and insulin glargine. It is a direct competitor in monoclonal antibody biosimilars with global commercial reach and active pipeline expansion.

4Sandoz
TypeBroad incumbent
Description

Sandoz is the global biosimilars and generics leader (Novartis spin-off) with one of the broadest biosimilar portfolios including Hyrimoz (adalimumab), Omnitrope (somatropin), and Erelzi (etanercept). It is also a commercialization partner for Alvotech but competes directly across the same molecule targets.

TypeBroad incumbent
Description

Amgen is a leading global biopharmaceutical company that both develops innovative biologics (e.g., Enbrel, Prolia, Eylea co-marketer) and has built a biosimilar portfolio through Amgevita/Soliris biosimilar programs. It is both a potential competitor and the originator of several reference biologics Alvotech is targeting.

TypeBroad incumbent
Description

Pfizer operates a broad biosimilars portfolio (e.g., Inflectra/Remsima with Celltrion, Nivestym, Retacrit, Zirabev) alongside its innovative biologics business. It is a broad incumbent across multiple therapeutic areas where Alvotech is developing biosimilars.

TypeBroad incumbent
Description

Teva is Alvotech's flagship commercialization partner in the US and select global markets, but also operates its own biosimilars business (e.g., Truxima, Herzuma partnerships) and broad specialty/generics portfolio. It represents both a critical commercial channel and a broader incumbent competitor.

TypeEmerging player
Description

Coherus BioSciences is a US biosimilars company with approved products including Udenyca (pegfilgrastim biosimilar), Cimerli (ranibizumab), and Yusimry (adalimumab). It is an emerging competitor in ophthalmology and oncology biosimilars with overlapping therapeutic focus.

9Shanghai Henlius Biotech
TypeEmerging player
Description

Shanghai Henlius is a Chinese biopharmaceutical company with an approved biosimilars portfolio (e.g., trastuzumab HLX02, rituximab HLX01, adalimumab HLX03) and an extensive pipeline. It is an emerging competitor in global biosimilar markets, particularly in oncology and immunology.

TypeEmerging player
Description

Polpharma Biologics is a European biosimilars developer with a pipeline including ranibizumab, natalizumab, and pertuzumab biosimilars. It is an emerging direct competitor in ophthalmology and immunology biosimilars with overlapping molecule targets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Alvotech

Biosimilar Pharmaceuticalsalvotech.com

Alvotech is a global biotechnology company that develops and manufactures biosimilar monoclonal antibodies for immunology, ophthalmology, oncology, and bone health, commercializing them through global partners (Teva, Sandoz, Advanz, Dr. Reddy's) and direct US sales, with five approved biosimilars and nine pipeline candidates.

What Alvotech does

Alvotech is a global biotechnology company that develops, manufactures, and commercializes biosimilar versions of high-cost biologic medicines. Founded in 2013 and headquartered in Reykjavík, Iceland, the company operates a vertically integrated platform spanning cell line development, analytical characterization, clinical development, regulatory submissions, single-use bioreactor manufacturing (in Reykjavik and Jülich, Germany), and fill/finish (via the acquired Ivers-Lee facility in Burgdorf, Switzerland). The portfolio is focused exclusively on monoclonal antibody biosimilars across immunology, ophthalmology, oncology, and bone health, with five approved products globally (AVT02 adalimumab, AVT04 ustekinumab, AVT03 denosumab, AVT05 golimumab, AVT06 aflibercept) and nine candidates in the pipeline. Alvotech is publicly listed on NASDAQ (ALVO) and trades Swedish Depositary Receipts on Nasdaq Stockholm.

The company monetizes its biosimilars through a hybrid model: direct sales to wholesalers, distributors, and pharmacies in the United States where Alvotech is the Marketing Authorization Holder (e.g., Simlandi for adalimumab, Selarsdi for ustekinumab), combined with regional commercialization partnerships covering most other geographies. Teva handles the United States and select markets for multiple programs; Sandoz distributes in Canada, Australia, and New Zealand; Advanz Pharma leads European commercialization (including the December 2025 launch of Gobivaz, the first-in-market Simponi biosimilar); and Dr. Reddy's handles selected programs. Revenue is also generated through licensing royalties, milestone payments, and supply agreements with these partners. End customers are healthcare providers, government health systems, payers, wholesalers, and pharmacies across the US, Europe, Japan, China, Latin America, Africa, and the Middle East.

Alvotech reported FY2025 revenue of approximately $593 million and is guiding $650–700 million for FY2026. The company has financed growth through a mix of equity, convertible bonds, and senior debt, with a $965M GoldenTree-led refinancing in June 2024 and multiple subsequent capital raises in 2025–2026. The business faces near-term execution risk: an FDA Complete Response Letter in November 2025 regarding the Reykjavik manufacturing facility has delayed AVT05, triggered securities litigation, and pressured the share price, while the late-stage pipeline (AVT05, AVT06, AVT16/AVT80) is central to the 2026–2027 growth thesis. A leadership transition in early 2026 — Lisa Graver replacing founder Róbert Wessman as CEO — accompanies the operational recalibration.

Alvotech firmographics

Firmographics
Name
Alvotech
Legal name
Alvotech hf
Website
https://alvotech.com
Company type
Public
Founded year
2013
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Alvotech is a global biotechnology company that develops and manufactures biosimilar monoclonal antibodies for immunology, ophthalmology, oncology, and bone health, commercializing them through global partners (Teva, Sandoz, Advanz, Dr. Reddy's) and direct US sales, with five approved biosimilars and nine pipeline candidates.
Ownership category
akta.pro rank

Alvotech industry classification

Industry
Product category
Biosimilar Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAHAL
Biosimilar Commercialization & Market Access (pricing, tendering, interchangeability, distribution)
SECONDARYHLAGAMAD
Specialty Pharma & Biologics Distribution (GDP-compliant)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Supply Chain, Logistics & Cold Chain for Life Sciences

Keywords

  • Biosimilar medicines
  • Monoclonal antibody development
  • Biologics manufacturing
  • Biopharmaceutical development
  • Cell line engineering

Where Alvotech is headquartered

Location

Headquarters

HQ city
Reykjavík
HQ country
Iceland
HQ region
Europe

Offices10 records

Markets served

Alvotech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Technology or R&D, Personnel, Marketing or Sales, Supply Chain

Revenue model

  1. Biosimilar product sales: Revenue from the sale of approved biosimilars directly (where Alvotech is MAH) and through commercialization partners in multiple geographies. Includes AVT02 (adalimumab biosimilar) and other approved products.
  2. Licensing royalties and milestone payments: Revenue from licensing, royalty, and milestone arrangements with commercial partners including Teva, Sandoz, Advanz Pharma, Dr. Reddy's, and Regeneron (settlement/licensing agreement). Includes upfront, milestone, and royalty components tied to development, regulatory, and commercial events.
  3. Supply and commercialization agreements: Revenue generated through supply and commercialization agreements with regional partners covering defined territories (e.g., Sandoz for Canada/Australia/New Zealand; Advanz Pharma for Europe).

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goBiosimilar medicines pricing not publicly disclosed

Go-to-market motion3 records

Distribution channels5 records

Marketing channels3 records

Alvotech product offering

Product offering

Core offering

Alvotech develops, manufactures, and commercializes biosimilar medicines—biologic medicines that are highly similar to already-approved reference biologics—focused on monoclonal antibody therapies. The company operates a vertically integrated platform covering cell line development, process and analytical development, clinical studies, regulatory submissions, manufacturing, and fill/finish. It markets its products either directly in the US (where it is the Marketing Authorization Holder) or through regional commercialization partners (Teva, Sandoz, Advanz Pharma, Dr. Reddy's) across Europe, Canada, Australia, New Zealand, Japan, China, Latin America, Africa, and the Middle East.

Differentiator

Problem solved

Functional benefit

Brands

  • Simlandi (adalimumab-ryvk): U.S. marketed biosimilar product for which Alvotech is the Marketing Authorization Holder in the U.S. (adalimumab biosimilar).
  • Selarsdi (ustekinumab-aekn)
  • Gobivaz

Products and services

  • Simlandi (AVT02, adalimumab-ryvk) Biosimilar of Humira (adalimumab) for the treatment of immunology conditions including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis. Marketed by Alvotech in the US.
  • Selarsdi (AVT04, ustekinumab-aekn) Biosimilar of Stelara (ustekinumab) for the treatment of immunology conditions including plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Marketed by Alvotech in the US.
  • AVT03 (denosumab biosimilar)
  • Gobivaz (AVT05, golimumab biosimilar) Biosimilar of Simponi (golimumab) for the treatment of inflammatory conditions including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. Marketed as Gobivaz in Europe by Advanz Pharma; marketed in the US by Teva (as AVT05) following FDA approval.
  • AVT06 (aflibercept biosimilar) Biosimilar of Eylea (aflibercept) for the treatment of ophthalmology conditions including neovascular (wet) age-related macular degeneration, diabetic macular edema, and other retinal disorders. Developed under partnership with Teva for US commercialization.
  • AVT16 (vedolizumab biosimilar, proposed interchangeable) Proposed interchangeable biosimilar of Entyvio (vedolizumab) for the treatment of ulcerative colitis and Crohn's disease. Developed under partnership with Teva Pharmaceutical Industries, with Alvotech handling development and manufacturing.
  • AVT80 (vedolizumab biosimilar, subcutaneous) Proposed subcutaneous biosimilar of Entyvio (vedolizumab) for the treatment of ulcerative colitis and Crohn's disease, complementing the intravenous AVT16 program. The successful PK study supports regulatory submissions for both products.

Quantifiable outcome

  • $593M in revenue (2025 reference figure in source)
  • +2 more outcomes

Companies that use Alvotech

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Alvotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Alvotech partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered flagship, core and minor.

  • Teva Pharmaceutical IndustriesflagshipStrategic or Co-development PartnerTeva is Alvotech's strategic commercialization partner for multiple biosimilars (including AVT05, AVT06, AVT16 and others). The partnership covers US commercialization and select global markets and represents one of Alvotech's most important commercial relationships.
  • SandozcoreChannel Partner/ Reseller/ DistributorSupply and commercialization agreement covering Canada, Australia, and New Zealand for Alvotech biosimilars. Sandoz distributes Alvotech's products in these regional markets under defined territory terms.
  • Advanz PharmacoreChannel Partner/ Reseller/ DistributorEuropean commercialization partner for Gobivaz (golimumab biosimilar / Simponi biosimilar) and additional Alvotech biosimilars. Advanz Pharma leads the European launch and distribution of these products.
  • Dr. Reddy's LaboratoriescoreStrategic or Co-development PartnerStrategic commercialization and co-development partner for AVT03 (denosumab biosimilar) and related biosimilar programs. The partnership supports Alvotech's reach into selected markets and shared development effort.
  • RegeneroncoreOEM/ Whitelabel/ Licensing PartnerSettlement and licensing agreement related to AVT06 (Eylea / aflibercept biosimilar). Resolves patent dispute and enables Alvotech to develop and commercialize its aflibercept biosimilar under the terms of the agreement.
  • Ivers-Lee (Burgdorf, Switzerland)minorImplementation/ SI/ Consulting PartnerAssembly and packaging partner supporting Alvotech's fill/finish operations at the Burgdorf, Switzerland site.
  • GlycoThera GmbHminorStrategic or Co-development PartnerR&D subsidiary contributing to Alvotech's biosimilar research and development capabilities.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Alvotech competitors and assessment

Company assessment

Direct peers

  • Samsung Bioepis: Samsung Bioepis is a biosimilars-focused biotech with an approved portfolio spanning immunology (adalimumab, etanercept), ophthalmology (ranibizumab), and oncology (trastuzumab, bevacizumab). It is a direct competitor in monoclonal antibody biosimilars with overlapping therapeutic-area focus and global commercialization partnerships.
  • Celltrion: Celltrion is a South Korean biosimilars leader with approved products including infliximab (Remsima), rituximab (Truxima), trastuzumab (Herzuma), and adalimumab (Yuflyma). It is a direct competitor across immunology and oncology biosimilars with vertically integrated manufacturing and global commercial reach.
  • Biocon Biologics: Biocon Biologics is a biosimilars-focused subsidiary of Biocon Limited with approved products including pegfilgrastim, trastuzumab, bevacizumab, and insulin glargine. It is a direct competitor in monoclonal antibody biosimilars with global commercial reach and active pipeline expansion.

Broad incumbents

  • Sandoz: Sandoz is the global biosimilars and generics leader (Novartis spin-off) with one of the broadest biosimilar portfolios including Hyrimoz (adalimumab), Omnitrope (somatropin), and Erelzi (etanercept). It is also a commercialization partner for Alvotech but competes directly across the same molecule targets.
  • Amgen: Amgen is a leading global biopharmaceutical company that both develops innovative biologics (e.g., Enbrel, Prolia, Eylea co-marketer) and has built a biosimilar portfolio through Amgevita/Soliris biosimilar programs. It is both a potential competitor and the originator of several reference biologics Alvotech is targeting.
  • Pfizer: Pfizer operates a broad biosimilars portfolio (e.g., Inflectra/Remsima with Celltrion, Nivestym, Retacrit, Zirabev) alongside its innovative biologics business. It is a broad incumbent across multiple therapeutic areas where Alvotech is developing biosimilars.
  • Teva Pharmaceutical Industries: Teva is Alvotech's flagship commercialization partner in the US and select global markets, but also operates its own biosimilars business (e.g., Truxima, Herzuma partnerships) and broad specialty/generics portfolio. It represents both a critical commercial channel and a broader incumbent competitor.

Emerging players

  • Coherus BioSciences: Coherus BioSciences is a US biosimilars company with approved products including Udenyca (pegfilgrastim biosimilar), Cimerli (ranibizumab), and Yusimry (adalimumab). It is an emerging competitor in ophthalmology and oncology biosimilars with overlapping therapeutic focus.
  • Shanghai Henlius Biotech: Shanghai Henlius is a Chinese biopharmaceutical company with an approved biosimilars portfolio (e.g., trastuzumab HLX02, rituximab HLX01, adalimumab HLX03) and an extensive pipeline. It is an emerging competitor in global biosimilar markets, particularly in oncology and immunology.
  • Polpharma Biologics: Polpharma Biologics is a European biosimilars developer with a pipeline including ranibizumab, natalizumab, and pertuzumab biosimilars. It is an emerging direct competitor in ophthalmology and immunology biosimilars with overlapping molecule targets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Alvotech social profiles

Digital presence

Alvotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Alvotech leadership team

Management profile

Number of profiles

Profiles11 records

Alvotech subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

Alvotech funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Alvotech M&A and investment

M&A and investment

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alvotech

What does Alvotech do?

Alvotech develops, manufactures, and commercializes biosimilar medicines—biologic medicines that are highly similar to already-approved reference biologics—focused on monoclonal antibody therapies. The company operates a vertically integrated platform covering cell line development, process and analytical development, clinical studies, regulatory submissions, manufacturing, and fill/finish. It markets its products either directly in the US (where it is the Marketing Authorization Holder) or through regional commercialization partners (Teva, Sandoz, Advanz Pharma, Dr. Reddy's) across Europe, Canada, Australia, New Zealand, Japan, China, Latin America, Africa, and the Middle East.

Is Alvotech a public or private company?

Alvotech is a public company. It is classified as public and is currently operating.

When was Alvotech founded?

Alvotech was founded in 2013. It employs 1,001 to 5,000 people.

Where is Alvotech based?

Alvotech is headquartered in Reykjavík, Iceland, in the Europe region.

How does Alvotech make money?

Three revenue lines are on record. Biosimilar product sales are the primary driver. The others are licensing royalties and milestone payments and supply and commercialization agreements.

Who are Alvotech's main competitors?

Direct peers on record are Samsung Bioepis, Celltrion and Biocon Biologics. Broad incumbents are Sandoz, Amgen, Pfizer and Teva Pharmaceutical Industries. Emerging players are Coherus BioSciences, Shanghai Henlius Biotech and Polpharma Biologics.

Does Alvotech have an API?

No public API is recorded for Alvotech.

What industry is Alvotech in?

Alvotech's product category is Biosimilar Pharmaceuticals. Its primary akta.pro industry code is HLAAAHAL, Biosimilar Commercialization & Market Access (pricing, tendering, interchangeability, distribution), with a secondary code of HLAGAMAD, Specialty Pharma & Biologics Distribution (GDP-compliant). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comAlvotech at Jefferies Global Healthcare Conference: biosimilar push gains paceAlvotech presented its biosimilar strategy at the Jefferies Global Healthcare Conference, citing over $2 billion in investments and a $600 million top line. The company expects three biosimilar approvals in December 2024 and targets operational cash positivity in Q4 2024. It also highlighted legal and regulatory hurdles tied to Simponi and Eylea high-dose.Seeking AlphaAlvotech (ALVO) Presents at UBS Global Biopharma Conference 2026 TranscriptAlvotech presented at the UBS Global Biopharma Conference, with founder Robert Wessman outlining the company's biosimilar pipeline. The company has invested over $2 billion in infrastructure and built a commercial network with 20 partners, including Teva and Advanz. Wessman stated Alvotech has one of the largest pipelines in hub development.MarketWatchAmneal's Asthma Treatment Receives European Commission Marketing ApprovalThe European Commission granted marketing authorization for Adcomfo, an add-on treatment for severe persistent allergic asthma, developed by Kashiv BioSciences and Alvotech. The approval follows a positive EMA committee opinion in September, and the drug also received UK authorization in March. Amneal's biosimilar application for Novartis' XOLAIR is under review in the U.S.Investing.comAlvotech at UBS biopharma conference: pipeline, launches and scaleAlvotech reported Q3 2024 revenue of $110 million and EBITDA of $31 million, expecting a record Q4. The company has about 30 in-house biosimilar products and three FDA decisions on December 4, 2024. It is expanding supply capacity with Lotte and Fujifilm, targeting drug substance in late 2025 and finished products by 2028.Simply Wall StWhy Alvotech (ALVO) Is Down 10.3% And What's NextAlvotech reported a net loss of $140.66 million for the nine months ended September 30, 2026, down from $136.47 million net income a year earlier. The loss, combined with less than one year of cash runway and higher interest costs, pressures the company to meet its 2026 revenue and EBITDA guidance. Analysts project revenue of $984 million and earnings of $202.4 million by 2029.YahooAlvotech Stock After Earnings Loss What ChangedAlvotech reported a net loss of $140.66 million for the nine months ended September 30, 2026, down from $136.47 million a year earlier, with EPS shifting from $0.47 to a $0.45 loss. The loss reflects operating pressures on its biosimilar platform, with management reaffirming 2026 revenue and EBITDA targets.Simply Wall StAlvotech (ALVO) Following Pipeline And Earnings Update, Is The Selloff A Bargain Or Priced In?Alvotech reported a US$140.66 million net loss for the first nine months of 2026, and its stock fell 10.28% in one day. Analysts estimate a fair value of $7.20 per share, implying the stock is undervalued, but execution and regulatory risks remain.Seeking AlphaAlvotech targets $650M-$700M revenue and $180M-$220M EBITDA as it expects Q4 to be “the strongest” in company historyAlvotech expects Q4 2026 to be its strongest quarter, targeting $650M-$700M revenue and $180M-$220M EBITDA. The company anticipates FDA approvals on three products, including AVT05, before year-end.Seeking AlphaAlvotech falls on Q3 resultsAlvotech fell about 6% in Thursday afternoon trading after missing on Q3 results. The company reiterated full-year revenue guidance of $650M-$700M, with the midpoint above consensus. Revenue growth was -12.07% year-over-year.